循环肿瘤细胞与循环肿瘤DNA检测在转移性尿路上皮癌中提供互补信息
该初步研究对16例转移性尿路上皮癌患者进行CTC与ctDNA头对头比较。75%患者可检出CTC,73%可检出体细胞突变,两者无相关性;91%患者血浆突变获得组织确认,且血浆中检出组织未见的可操作突变。ctDNA分数>2%与更差总生存显著相关(p=0.039),而CTC检出无显著关联(p=0.46)。
要点
- CTC与ctDNA在转移性尿路上皮癌中提供互补信息,CTC或更适于研究肿瘤生物学特征,ctDNA或更适于早期检测。
- ctDNA分数>2%与更差总生存显著相关(p=0.039),CTC检出与总生存无显著关联(p=0.46)。
- 血浆中可检出组织未见的可操作突变,提示液体活检可补充组织检测。
核心结论
- CTC与ctDNA两种液体活检在转移性尿路上皮癌中均显示应用前景,且提供互补信息,值得进一步研究。
研究设计与样本
- 初步研究,对16例转移性尿路上皮癌患者采集配对的CTC与ctDNA样本进行头对头比较。
- CTC采用RareCyte直接成像平台以细胞角蛋白和/或EpCAM阳性定义,ctDNA采用PlasmaSelect64探针捕获法检测。
主要发现
- 75%患者可检出CTC,73%患者可检出体细胞突变,CTC计数与ctDNA之间无相关性。
- 91%患者至少一个血浆突变获得组织确认,且血浆中检出若干组织未见的可操作突变。
- ctDNA分数>2%与更差总生存显著相关(p=0.039),CTC检出与总生存无显著关联(p=0.46)。
- 预定义基因面板用于ctDNA检测在转移性尿路上皮癌中检出率高但不完全,与定制组织个性化检测方法的报道相似。
关键数值与推荐
- CTC阳性定义:细胞角蛋白和/或EpCAM阳性(RareCyte直接成像平台)。
- ctDNA检测:PlasmaSelect64探针捕获法。
- ctDNA分数>2%与更差总生存显著相关(p=0.039)。
- CTC检出与总生存无显著关联(p=0.46)。
临床怎么用
- CTC或更适于研究患者肿瘤的生物学特征,ctDNA或更适于早期检测。
- 血浆ctDNA可检出组织未见的可操作突变,提示液体活检可补充组织检测用于临床决策。
局限性
- 初步研究仅纳入16例转移性尿路上皮癌患者,样本量小。
- 预定义基因面板用于ctDNA检测的检出率高但不完全。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite considerable advances in the management of urothelial carcinoma (UC), better risk stratification and enhanced detection of minimal residual disease are still urgent priorities to prolong survival while avoiding the morbidity of overtreatment. Circulating tumor cells and DNA (CTCs, ctDNA) are two biologically distinct "liquid biopsies" that may potentially address this need, although they have been understudied in UC to date and their relative utility is unknown. To this end, matched CTC and ctDNA samples were collected for a head-to-head comparison in a pilot study of 16 patients with metastatic UC. CTCs were defined as cytokeratin- and/or EpCAM-positive using the RareCyte direct imaging platform. ctDNA was assayed using the PlasmaSelect64 probe-capture assay. 75% of patients had detectable CTCs, and 73% had detectable somatic mutations, with no correlation between CTC count and ctDNA. 91% of patients had tissue confirmation of at least one plasma mutation and, importantly, several clinically actionable mutations were detected in plasma that were not found in the matching tumor. A ctDNA fraction of >2% was significantly associated with worse overall survival (p=0.039) whereas CTC detection was not (p=0.46). Notably, using a predefined gene panel for ctDNA detection had a high but not complete detection rate in metastatic UC, similar to what has been described for a custom tissue-personalized assay approach. In sum, both liquid biopsies show promise in UC and deserve further investigation. PATIENT SUMMARY: New "liquid biopsy" blood tests are emerging for urothelial cancer aimed at early detection and avoiding overtreatment. Our results suggest that two such tests provide complementary information: circulating tumor cells may be best for studying the biological features of a person's cancer, whereas circulating tumor DNA may be better for early detection.
引用
- Chalfin HJ, Glavaris SA, Gorin MA, et al. Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer. Eur Urol Oncol. 2019. PMID: 31563523. doi:10.1016/j.euo.2019.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。